Portal de Periódicos da CAPES

Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?

2014; Future Medicine; Volume: 10; Issue: 2 Linguagem: Inglês

10.2217/fon.14.6

1744-8301

Ramón Salazar, Julieta Grasselli, Cristina Santos, Josep Tabernero,

Hepatocellular Carcinoma Treatment and Prognosis

Future OncologyVol. 10, No. 2 EditorialTenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?Ramon Salazar, Julieta Grasselli, Cristina Santos & Josep TaberneroRamon Salazar* Author for correspondenceMedical Oncology Department, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. , Julieta GrasselliMedical Oncology Department, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain, Cristina SantosMedical Oncology Department, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain & Josep TaberneroMedical Oncology Department, Vall d'Hebron University Hospital & Institute of Oncology (VHIO), Barcelona, SpainPublished Online:3 Feb 2014https://doi.org/10.2217/fon.14.6AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: bevacizumabcolon cancercolonic neoplasmstherapeuticstherapyReferences1 Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23),2335–2342 (2004).Crossref, Medline, CAS, Google Scholar2 Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol.23(16),3706–3712 (2005).Crossref, Medline, CAS, Google Scholar3 Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised Phase 3 trial. Lancet Oncol.14(11),1077–1085 (2013).Crossref, Medline, CAS, Google Scholar4 Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26(12),2013–2019 (2008).Crossref, Medline, CAS, Google Scholar5 Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12),1539–1544 (2007).Crossref, Medline, CAS, Google Scholar6 Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol.14(1),29–37 (2013).Crossref, Medline, CAS, Google Scholar7 Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol.29(1),11–16 (2013).Crossref, Google Scholar8 de Gramont A, Van Cutsem E, Schmoll HJ et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a Phase 3 randomised controlled trial. Lancet Oncol.13(12),1225–1233 (2012).Crossref, Medline, CAS, Google Scholar9 Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA305(5),487–494 (2011).Crossref, Medline, CAS, Google Scholar10 Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell15(3),220–231 (2009).Crossref, Medline, CAS, Google Scholar11 Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol.23(22),4866–4875 (2005).Crossref, Medline, CAS, Google Scholar12 Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2),229–237 (2004).Crossref, Medline, CAS, Google Scholar13 Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol.22(7),1209–1214 (2004).Crossref, Medline, CAS, Google Scholar14 Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22(1),23–30 (2004).Crossref, Medline, CAS, Google Scholar15 Goldberg RM, Sargent DJ, Morton RF et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J. Clin. Oncol.24(21),3347–3353 (2006).Crossref, Medline, CAS, Google Scholar16 Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol.25(30),4779–4786 (2007).Crossref, Medline, CAS, Google Scholar17 Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol.26(12),2006–2012 (2008).Crossref, Medline, CAS, Google Scholar18 Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol.26(21),3523–3529 (2008).Crossref, Medline, CAS, Google Scholar19 Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J. Clin. Oncol.26(4),689–690 (2008).Crossref, Medline, Google Scholar20 Petrelli F, Borgonovo K, Cabiddu M et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin. Colorectal Cancer12(3),145–151 (2013).Crossref, Medline, CAS, Google Scholar21 Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med.369(11),1023–1034 (2013).Crossref, Medline, CAS, Google Scholar22 Stintzing S, Jung A, Rossius L et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized Phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at: European Cancer Congress 2013. Amsterdam, The Netherlands, 28 September 2013 (Abstract LBA E17- 7073).Google Scholar23 Hegde PS, Jubb AM, Chen D et al. Predictive impact of circulating vascular endothelial growth factor in four Phase III trials evaluating bevacizumab. Clin. Cancer Res.19(4),929–937 (2013).Crossref, Medline, CAS, Google Scholar24 Hurwitz HI, Douglas PS, Middleton JP et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven Phase III studies. Oncologist18(3),273–280 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 10, No. 2 STAY CONNECTED Metrics Downloaded 129 times History Published online 3 February 2014 Published in print February 2014 Information© Future Medicine LtdKeywordsbevacizumabcolon cancercolonic neoplasmstherapeuticstherapyAcknowledgementsThe authors would like to thank L Vecchione (KU Leuven, NKI Amsterdam) for critical reading of the manuscript and S Kelly for English editing.Financial & competing interests disclosureR Salazar is a consultant and has a advisory role for Amgen, Merck KGaA, Novartis and Ipsen. He has also honoraria for presentations for Amgen, Merck KGaA, Novartis and Ipsen. J Tabernero is a consultant and has an advisory role for Amgen, Boehringer, Bristol-Myers Squibb, Genentech, Imclone, Lilly, Merck KGaA, Millennium, Novartis, Onyx, Pfizer, Roche, Sanofi and Celgene. He has also received honoraria for presentations for Amgen, Merck KGaA, Novartis, Roche and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download